Research programme: pancreatic exocrine insufficiency therapy - Novozymes/AbbVie

Drug Profile

Research programme: pancreatic exocrine insufficiency therapy - Novozymes/AbbVie

Alternative Names: SLV 340

Latest Information Update: 01 Feb 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novozymes A/S; Solvay
  • Developer AbbVie; Novozymes A/S
  • Class Pancreatic enzymes
  • Mechanism of Action Amylase stimulants; Lipase stimulants; Protease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pancreatic disorders

Most Recent Events

  • 01 Aug 2012 No development reported - Preclinical for Pancreatic disorders in European Union (unspecified route)
  • 31 Mar 2010 Preclinical development is ongoing in European Union
  • 31 Dec 2006 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top